Janus kinase inhibitors in rheumatoid arthritis: Clinical applications

Jennifer Walker, Malcolm Smith

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Tofacitinib, an oral Janus kinase inhibitor, is an effective treatment for rheumatoid arthritis. Adverse effects are generally mild and include cytopenias and hyperlipidaemia. Opportunistic infections such as herpes zoster may occur with tofacitinib.

Original languageEnglish
Pages (from-to)158-160
Number of pages3
JournalAustralian Prescriber
Volume37
Issue number5
DOIs
Publication statusPublished - 1 Oct 2014
Externally publishedYes

Bibliographical note

Except where otherwise noted, all articles published in Australian Prescriber can be used under the CC BY-NC-ND licence.

Keywords

  • Molecular targeted therapy
  • Tofacitinib
  • rheumatoid arthritis

Fingerprint Dive into the research topics of 'Janus kinase inhibitors in rheumatoid arthritis: Clinical applications'. Together they form a unique fingerprint.

  • Cite this